OBJECTIVE: To investigate whether the sheep xenograft model of human hematopoiesis can be used to mimic mobilization of human hematopoietic stem cells in vivo. MATERIAL AND METHODS: Sheep transplanted with 3.6 x 10(6) CD34+ from human adult bone marrow were mobilized 1.5 years posttransplantation with human granulocyte colony-stimulating factor for 5 days. At day 3 and 4 of mobilization, human cells were harvested from peripheral blood (PB) and bone marrow (BM) and were injected into secondary sheep recipients (n = 6) and these animals were analyzed for the presence of human cells in their BM and PB, starting at 3.5 months posttransplantation. RESULTS: Maximum mobilization of human cells in PB occurred at day 3, with a 21-fold increase in total numbers of human cells, and a recovery of 5.5 x 10(4)/mL CD34+. In the BM, maximal numbers of human cells were achieved at day 4, with a 6.3-fold increase and a recovery of 1.5 x 10(4)/mL CD34+ cells. PB and BM mobilized human cells were then transplanted into new sheep recipients, and analysis at 3.5 months posttransplantation demonstrated that levels of human cell engraftment in BM of the group transplanted with mobilized PB were significantly lower than those transplanted with BM cells (0.6% +/- 0.1% vs 8.0% +/- 1.8%). Furthermore, in sheep transplanted with mobilized PB, the levels of human cells in circulation remained 2.5-fold higher than the levels of human cells found in their BM. CONCLUSION: Mobilization of human cells in the sheep model parallels human PB and BM hematopoietic stem cells (HSC) mobilization in healthy human donors in their ability to engraft, differentiate, and repopulate secondary hosts. Thus, this model can become a useful tool to study mobilization regimens, mechanisms, and quality of products obtained.
OBJECTIVE: To investigate whether the sheep xenograft model of human hematopoiesis can be used to mimic mobilization of human hematopoietic stem cells in vivo. MATERIAL AND METHODS:Sheep transplanted with 3.6 x 10(6) CD34+ from human adult bone marrow were mobilized 1.5 years posttransplantation with human granulocyte colony-stimulating factor for 5 days. At day 3 and 4 of mobilization, human cells were harvested from peripheral blood (PB) and bone marrow (BM) and were injected into secondary sheep recipients (n = 6) and these animals were analyzed for the presence of human cells in their BM and PB, starting at 3.5 months posttransplantation. RESULTS: Maximum mobilization of human cells in PB occurred at day 3, with a 21-fold increase in total numbers of human cells, and a recovery of 5.5 x 10(4)/mL CD34+. In the BM, maximal numbers of human cells were achieved at day 4, with a 6.3-fold increase and a recovery of 1.5 x 10(4)/mL CD34+ cells. PB and BM mobilized human cells were then transplanted into new sheep recipients, and analysis at 3.5 months posttransplantation demonstrated that levels of human cell engraftment in BM of the group transplanted with mobilized PB were significantly lower than those transplanted with BM cells (0.6% +/- 0.1% vs 8.0% +/- 1.8%). Furthermore, in sheep transplanted with mobilized PB, the levels of human cells in circulation remained 2.5-fold higher than the levels of human cells found in their BM. CONCLUSION: Mobilization of human cells in the sheep model parallels human PB and BM hematopoietic stem cells (HSC) mobilization in healthy human donors in their ability to engraft, differentiate, and repopulate secondary hosts. Thus, this model can become a useful tool to study mobilization regimens, mechanisms, and quality of products obtained.
Authors: Tatiana Ulyanova; Linda M Scott; Gregory V Priestley; Yi Jiang; Betty Nakamoto; Pandelakis A Koni; Thalia Papayannopoulou Journal: Blood Date: 2005-03-15 Impact factor: 22.113
Authors: K Theilgaard-Mönch; K Raaschou-Jensen; H Andersen; C A Russell; L Vindeløv; N Jacobsen; E Dickmeiss Journal: Bone Marrow Transplant Date: 1999-02 Impact factor: 5.483
Authors: B L Ziegler; M Valtieri; G A Porada; R De Maria; R Müller; B Masella; M Gabbianelli; I Casella; E Pelosi; T Bock; E D Zanjani; C Peschle Journal: Science Date: 1999-09-03 Impact factor: 47.728
Authors: Smita Bhatia; Leslie L Robison; Liton Francisco; Andrea Carter; Yan Liu; Marcia Grant; K Scott Baker; Henry Fung; James G Gurney; Philip B McGlave; Auayporn Nademanee; Norma K C Ramsay; Anthony Stein; Daniel J Weisdorf; Stephen J Forman Journal: Blood Date: 2005-02-08 Impact factor: 22.113
Authors: Jessica L Skopal-Chase; John S Pixley; Alireza Torabi; Mihai C Cenariu; Anupama Bhat; David S Thain; Nicole M Frederick; Daria M Groza; Esmail D Zanjani Journal: Fetal Diagn Ther Date: 2009-02-25 Impact factor: 2.587
Authors: Adel Ersek; John S Pixley; A Daisy Goodrich; Christopher D Porada; Graca Almeida-Porada; David S Thain; Esmail D Zanjani Journal: Exp Hematol Date: 2010-02-17 Impact factor: 3.084
Authors: James E Fisher; Joseph B Lillegard; Travis J McKenzie; Brian R Rodysill; Peter J Wettstein; Scott L Nyberg Journal: Liver Transpl Date: 2013-03 Impact factor: 5.799
Authors: Christopher D Porada; Duygu D Harrison-Findik; Chad Sanada; Vincent Valiente; David Thain; Paul J Simmons; Graça Almeida-Porada; Esmail D Zanjani Journal: Exp Hematol Date: 2008-12 Impact factor: 3.084